Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Authors: Bhumsuk Keam, Seock-Ah Im, Youngil Koh, Sae-Won Han, Do-Youn Oh, Nariya Cho, Jee Hyun Kim, Wonshik Han, Keon Wook Kang, Woo Kyung Moon, Tae-You Kim, In Ae Park, Dong-Young Noh, June-Key Chung, Yung-Jue Bang

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

This study was aimed 1) to investigate the predictive value of FDG PET/CT (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) for histopathologic response and 2) to explore the results of FDG PET/CT by molecular phenotypes of breast cancer patients who received neoadjuvant chemotherapy.

Methods

Seventy-eight stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. FDG PET/CTs were acquired before chemotherapy and after the first cycle of chemotherapy for evaluating early metabolic response.

Results

The mean pre- and post-chemotherapy standard uptake value (SUV) were 7.5 and 3.9, respectively. The early metabolic response provided by FDG PET/CT after one cycle of neoadjuvant chemotherapy was correlated with the histopathologic response after completion of neoadjuvant chemotherapy (P = 0.002). Sensitivity and negative predictive value were 85.7% and 95.1%, respectively. The estrogen receptor negative phenotype had a higher pre-chemotherapy SUV (8.6 vs. 6.4, P = 0.047) and percent change in SUV (48% vs. 30%, P = 0.038). In triple negative breast cancer (TNBC), the pre-chemotherapy SUV was higher than in non-TNBC (9.8 vs. 6.4, P = 0.008).

Conclusions

The early metabolic response using FDG PET/CT could have a predictive value for the assessment of histopathologic non-response of stage II/III breast cancer treated with neoadjuvant chemotherapy. Our findings suggest that the initial SUV and the decline in SUV differed based on the molecular phenotype.

Trial Registration

ClinicalTrials.gov: NCT01396655
Appendix
Available only for authorised users
Literature
1.
Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Pisani P, Park JG: Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005, 37: 325-331. 10.4143/crt.2005.37.6.325.CrossRefPubMedPubMedCentral
2.
Esteva FJ, Hortobagyi GN: Locally advanced breast cancer. Hematol Oncol Clin North Am. 1999, 13: 457-472. 10.1016/S0889-8588(05)70065-4. viiCrossRefPubMed
3.
Estevez LG, Gradishar WJ: Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004, 10: 3249-3261. 10.1158/1078-0432.CCR-03-0133.CrossRefPubMed
4.
Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol. 2003, 21: 2600-2608. 10.1200/JCO.2003.01.136.CrossRefPubMed
5.
Couturier O, Jerusalem G, N'Guyen JM, Hustinx R: Sequential positron emission tomography using [18f]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006, 12: 6437-6443. 10.1158/1078-0432.CCR-06-0383.CrossRefPubMed
6.
Hodgson NC, Gulenchyn KY: Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol. 2008, 26: 712-720. 10.1200/JCO.2007.13.8412.CrossRefPubMed
7.
Lee JH, Rosen EL, Mankoff DA: The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 2--response to therapy, other indications, and future directions. J Nucl Med. 2009, 50: 738-748. 10.2967/jnumed.108.061416.CrossRefPubMed
8.
Sloka JS, Hollett PD, Mathews M: A quantitative review of the use of fdg-pet in the axillary staging of breast cancer. Med Sci Monit. 2007, 13: RA37-46.PubMed
9.
Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, Pinedo HM, Hoekstra OS: Preoperative [18f] fdg-pet after chemotherapy in locally advanced breast cancer: Prognostic value as compared with histopathology. Ann Oncol. 2008, 19: 1573-1577. 10.1093/annonc/mdn185.CrossRefPubMed
10.
Kim SJ, Kim SK, Lee ES, Ro J, Kang S: Predictive value of [18f]fdg pet for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 2004, 15: 1352-1357. 10.1093/annonc/mdh345.CrossRefPubMed
11.
Krak NC, Hoekstra OS, Lammertsma AA: Measuring response to chemotherapy in locally advanced breast cancer: Methodological considerations. Eur J Nucl Med Mol Imaging. 2004, 31 (Suppl 1): S103-111.CrossRefPubMed
12.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M: Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18f]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006, 24: 5366-5372. 10.1200/JCO.2006.05.7406.CrossRefPubMed
13.
Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M: Positron emission tomography using [(18)f]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000, 18: 1689-1695.PubMed
14.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009, 116: 153-160. 10.1007/s10549-008-0160-9.CrossRefPubMed
15.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic impact of clinicopathologic parameters in stage ii/iii breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer. BMC Cancer. 2007, 7: 203-10.1186/1471-2407-7-203.CrossRefPubMedPubMedCentral
16.
Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF: Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002, 20: 379-387. 10.1200/JCO.20.2.379.CrossRefPubMed
17.
Kong X, Moran MS, Zhang N, Haffty B, Yang Q: Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011, 47: 2084-2090. 10.1016/j.ejca.2011.06.014.CrossRefPubMed
18.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17: 460-469.PubMed
19.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093/jnci/92.3.205.CrossRefPubMed
20.
Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW, Whelan TJ, Pfister DG: Postmastectomy radiotherapy: Clinical practice guidelines of the american society of clinical oncology. J Clin Oncol. 2001, 19: 1539-1569.PubMed
21.
Han S, Kim SB, Kang SS, Noh WC, Paik NS, Chang ES, Kim JR, Lim SH, Park HS: A phase ii study of neoadjuvant docetaxel plus doxorubicin (kbcs-01) in stage ii, iii breast cancer. Breast Cancer Res Treat. 2006, 98: 57-61. 10.1007/s10549-005-9131-6.CrossRefPubMed
22.
Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic significance of bcl-2 expression in stage iii breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 2007, 7: 63-10.1186/1471-2407-7-63.CrossRefPubMedPubMedCentral
23.
Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE: Her2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002, 77: 148-154. 10.4065/77.2.148.CrossRefPubMed
24.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13: 2329-2334. 10.1158/1078-0432.CCR-06-1109.CrossRefPubMed
25.
Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998, 77: 621-626. 10.1038/bjc.1998.99.CrossRefPubMedPubMedCentral
26.
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007, 25: 2650-2655. 10.1200/JCO.2006.08.2271.CrossRefPubMed
27.
Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989, 10: 1-10. 10.1016/0197-2456(89)90015-9.CrossRefPubMed
28.
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M: Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol. 2000, 18: 3495-3502.PubMed
29.
Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN: The role of (18)f-fdg pet/ct in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009
30.
Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F: [18f]fdg-pet predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007, 34: 1915-1924. 10.1007/s00259-007-0459-5.CrossRefPubMed
31.
Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, Guzman F, Rubi S, Lomena FJ, Pons F: (18)f-fdg pet/ct for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009
32.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA: Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008, 26: 4449-4457. 10.1200/JCO.2007.15.4385.CrossRefPubMedPubMedCentral
33.
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB: Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003, 44: 1806-1814.PubMed
34.
McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, Smith TA, Hutcheon AW, Miller ID, Smith IC, Heys SD: Monitoring primary breast cancer throughout chemotherapy using fdg-pet. Breast Cancer Res Treat. 2007, 102: 75-84. 10.1007/s10549-006-9316-7.CrossRefPubMed
35.
Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N: Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18f]fluorodeoxyglucose. J Clin Oncol. 2009, 27: 535-541.CrossRefPubMed
36.
Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF: Positron emission tomography using [(18)f]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000, 18: 1676-1688.PubMed
37.
Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Shin KH, Lee S, Kim SW, Kang HS, Ro J: Prognostic impact of [(18)f] fdg-pet in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2009
38.
Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M: Glucose metabolism of breast cancer assessed by 18f-fdg pet: Histologic and immunohistochemical tissue analysis. J Nucl Med. 2001, 42: 9-16.PubMed
39.
Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY: Ki-67 expression gives additional prognostic information on st. Gallen 2007 and adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009
40.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A: Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/her2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: A potentially useful method for disease characterization. Cancer. 2008, 112: 995-1000. 10.1002/cncr.23226.CrossRefPubMed
Metadata
Title
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
Authors
Bhumsuk Keam
Seock-Ah Im
Youngil Koh
Sae-Won Han
Do-Youn Oh
Nariya Cho
Jee Hyun Kim
Wonshik Han
Keon Wook Kang
Woo Kyung Moon
Tae-You Kim
In Ae Park
Dong-Young Noh
June-Key Chung
Yung-Jue Bang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-452

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Hakai reduces cell-substratum adhesion and increases epithelial cell invasion

Research article

Increase in intracellular PGE2 induces apoptosis in Bax-expressing colon cancer cell

Case report

Peritoneal lymphomatosis confounded by prior history of colon cancer: a case report

Research article

The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors - results of a prospective study

Research article

Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility

Research article

SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits